PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma | MicrobiomeTrials← Back to trialsNCT06639607
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-30Est. Completion: 2031-08-31
Enrollment target: 68 participants Locations- Washington University School of Medicine, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Malignant Glioma
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radi…
Birmingham, United StatesEst. completion Jun 30, 2027
Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous SystemRecurrent Diffuse Intrinsic Pontine GliomaRecurrent Diffuse Midline Glioma, H3 K27-AlteredRecurrent LymphomaRecurrent Malignant Solid Neoplasm
Recurrent Primary Malignant Central Nervous System Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Primary Malignant Central Nervous System Neoplasm
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with so…
Birmingham, United StatesEst. completion Dec 31, 2026